Pre-Annual General Meeting Information • Oct 13, 2022
Pre-Annual General Meeting Information
Open in ViewerOpens in native device viewer
Circular to shareholders
The one hundred and eighth Annual General Meeting of Smiths Group plc will be held at Freshfields Bruckhaus Deringer, 100 Bishopsgate, London EC2P 2SR on Wednesday, 16 November 2022 at 11.00am
For those shareholders unable to attend the Annual General Meeting, the meeting will be webcast and may be viewed by registering on our website www.smiths.com.
If you are in any doubt as to any aspect of the proposals referred to in this document or as to the action you should take, you should seek your own advice from a stockbroker, solicitor, accountant, or other independent professional adviser who, if you are taking advice in the United Kingdom, is authorised under the Financial Services & Markets Act 2000.
If you have sold or otherwise transferred all of your shares, please pass this document together with the accompanying documents to the purchaser or transferee, or to the person who arranged the sale or transfer so they can pass these documents to the person who now holds the shares.
Notice is hereby given that the one hundred and eighth Annual General Meeting of Smiths Group plc (the 'Company') will be held at Freshfields Bruckhaus Deringer, 100 Bishopsgate, London EC2P 2SR on Wednesday, 16 November 2022 at 11.00am
Resolutions 1 to 16 and 21 are proposed as ordinary resolutions. Resolutions 17 to 20 (inclusive) are proposed as special resolutions.
for cash under the authority given by that resolution and/or to sell ordinary shares held by the Company as treasury shares for cash as if section 561 of the Act did not apply to any such allotment or sale, such authority to be limited:
such authority to expire (unless previously renewed, varied or revoked by the Company in general meeting) at the end of the next Annual General Meeting of the Company or, if earlier, the close of business on 31 January 2024 but, in each case, so that the Company may, before such expiry, make offers, and enter into agreements, which would, or might, require equity securities to be allotted (and treasury shares to be sold) after the authority expires and the Directors may allot equity securities (and sell treasury shares) under any such offer or agreement as if the authority had not expired.
For the purposes of this Resolution: (a) 'rights issue' means an offer to:
subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to treasury shares, fractional entitlements, record dates or legal, regulatory or practical problems in, or under the laws of, any territory or any other matter.
such authority to expire (unless previously renewed, varied or revoked by the Company in general meeting) at the end of the next Annual General Meeting of the Company or, if earlier, the close of business on 31 January 2024 but, in each case, so the Company may, before
such expiry, make offers, and enter into agreements, which would, or might, require equity securities to be allotted (and treasury shares to be sold) after the authority expires and the Directors may allot equity securities (and sell treasury shares) under any such offer or agreement as if the authority had not expired.
This authority is in addition to the previous authority conferred on the Company in accordance with Section 701 of the Act by shareholders at the General Meeting held on 17 November 2021 and is without prejudice to any market purchases already made or agreed to be made pursuant to such authority.
The authority hereby conferred shall expire at the conclusion of the next Annual General Meeting of the Company or, if earlier, the close of business on 31 January 2024. All existing authorisations and approvals relating to political donations or expenditure under Part 14 of the Act are hereby revoked without prejudice to any donation made or expenditure incurred prior to the date hereof pursuant to such authorisation or approval.
For the purposes of this resolution, the terms 'political donations', 'political parties', 'independent election candidates', 'political organisations' and 'political expenditure' have the meanings set out in Sections 363 to 365 of the Act.
By Order of the Board
COMPANY SECRETARY 13 October 2022
4th floor, 11-12 St James's Square London SW1Y 4LB
Registered in England and Wales no. 00137013
Resolutions 1 to 16 and 21 are proposed as ordinary resolutions. This means that for each of those resolutions to be passed, more than half of the votes cast must be in favour of the resolution. Resolutions 17 to 20 (inclusive) are proposed as special resolutions. This means that for each of those resolutions to be passed, at least three-quarters of the votes cast must be in favour of the resolution.
Your Directors believe that all the proposals to be considered at the Annual General Meeting (the 'AGM') are in the best interests of the Company and its shareholders as a whole, and recommend shareholders to vote in favour of the resolutions. The Directors intend to vote in favour of the resolutions in respect of their own beneficial holdings.
The Directors must present the reports of the Directors and the accounts of the Company for the year ended 31 July 2022 to shareholders at the AGM. The reports of the Directors (including the Strategic Report), the accounts, and the report of the Company's auditors on the accounts and on those parts of the Directors' Remuneration Report that are required to be audited are contained within the FY2022 Annual Report.
Under Section 420 of the Companies Act 2006 (the 'Act'), the Directors must prepare a remuneration report detailing the remuneration of the Directors and containing a statement by the Chair of the Remuneration & People Committee. The Act also requires that a resolution be put to shareholders each year for their approval of that report. This is an advisory resolution only.
A final dividend can only be paid after the shareholders have approved it at a general meeting. If the final dividend is approved, it will be payable on 18 November 2022 to shareholders on the register of members at 6.00pm on 21 October 2022 (the record date). From November 2019, Smiths Group plc stopped issuing dividend cheques. In order for shareholders to have dividends paid directly to their bank or building society account they should contact Equiniti for a copy of the Bank Mandate Form.
Richard Howes and Clare Scherrer were appointed to the Board since the last AGM and, in accordance with the Company's Articles of Association, will retire and stand for election at the AGM.
The Chairman confirms, on behalf of the Board, that each Director standing for election or re-election continues to be effective and demonstrates commitment to their respective roles.
See the appendix to the Notes on pages 9 and 10 for detailed biographies. Their biographies are also available on pages 58 and 59 of the FY2022 Annual Report and the Company's website, www.smiths.com. The Nomination & Governance Committee Report on page 66 of the FY2022 Annual Report provides further information in support of Director re-election.
The Board, on the advice of the Audit & Risk Committee (summarised in the Audit & Risk Committee Report on Page 69 of the FY2022 Annual Report), recommends the reappointment of KPMG LLP as auditor, to hold office until the next meeting before which the accounts are laid (Resolution 14).
Resolution 15 authorises the Audit & Risk Committee, acting for and on behalf of the Board, to determine the remuneration of KPMG LLP for their services as auditor.
The purpose of Resolution 16 (the 'allotment resolution') is to renew the Directors' power to issue and allot new shares in the Company.
The authority in Resolution 16 will allow the Directors to allot new shares in the Company or to grant rights to subscribe for or convert any security into shares in the Company up to a nominal value of £44,605,938, which is equivalent to approximately one third of the nominal amount of the ordinary share capital of the Company in issue on 5 October 2022.
As at 5 October 2022, the Company did not hold any treasury shares.
If the resolution is passed the authority will expire on the earlier of the close of business on 31 January 2024 and the end of the AGM due to be held in 2023, unless previously renewed, varied or revoked.
The Directors have no current intention to use this authority, but it is sought to ensure the Directors maintain maximum flexibility in response to capital management.
If the Directors wish to allot new shares and other equity securities, or sell treasury shares, for cash (other than in connection with an employee share scheme), company law requires that these shares are offered first to the shareholders, in proportion to their existing holdings.
The Directors consider it desirable to have the maximum flexibility permitted by corporate governance guidelines to respond to market developments and to enable allotments to take place to finance business opportunities without making a pre-emptive offer to existing shareholders. This cannot be done under the Act unless the shareholders have first waived their pre-emption rights. The purpose of Resolutions 17 and 18 (together the 'disapplication of pre-emption rights resolutions') is to enable shareholders to waive their pre-emption rights.
Resolution 17 authorises Directors to allot new shares, pursuant to the authority given by Resolution 16 (the 'allotment resolution'), or to sell treasury shares for cash:
in each case without the shares first being offered to existing shareholders in proportion to their existing holdings.
Resolution 18 additionally authorises the Directors to allot new shares (or sell treasury shares) for cash, without the shares first being offered to existing shareholders in proportion to their existing holdings, in connection with the financing (or refinancing, if the authority is to be used within six months after the original transaction) of an acquisition or specified capital investment which is announced contemporaneously with the allotment or which has taken place in the preceding six-month period and is disclosed in the announcement of the allotment.
The authority under Resolution 18 is limited to a nominal value of £6,690,890, equivalent to approximately 5% of the nominal value of the ordinary share capital of the Company in issue on 5 October 2022.
Taken together, the allotment resolution and the disapplication of pre-emption rights resolutions will allow the Directors to issue new shares for cash or to sell treasury shares without offering the shares first to existing shareholders in proportion to their existing holdings under the following circumstances:
(c) in connection with the financing or refinancing of an acquisition or specified capital investment which is announced contemporaneously with the allotment or which has taken place in the preceding six month period and is disclosed in the announcement of the allotment, with a nominal value equivalent to 5% of the present issued share capital
but subject to an overall aggregate limit equivalent to one-third of the present issued share capital.
The Directors intend to adhere to the provisions in the Pre-Emption Group's statement of Principles, as updated in March 2015, and not to allot shares for cash on a non-pre-emptive basis pursuant to the authority in Resolution 17 either in excess of an amount equal to 5% of the total issued ordinary share capital of the Company (excluding treasury shares) or in excess of an amount equal to 7.5% of the total issued ordinary share capital of the Company (excluding treasury shares) within a rolling three-year period, without prior consultation with shareholders. Adherence to the principles would not preclude issuances under the authority sought under Resolution 18.
The allotment and the disapplication of pre-emption rights resolutions comply with the Share Capital Management Guidelines issued by the Investment Association in July 2016 and the disapplication of pre- emption rights resolutions largely follow the resolution templates issued by the Pre-Emption Group in May 2016.
If the resolutions are passed, the authorities will expire on the earlier of the close of business on 31 January 2024 and the end of the AGM due to be held in 2023, unless previously renewed, varied or revoked.
As at 5 October 2022, the Company did not hold any treasury shares. If the Company were to create treasury shares, e.g. through the market purchase of its own shares, the subsequent sale of any treasury shares (or the use of treasury shares to satisfy obligations under the Company's share schemes and plans) would be counted as equivalent to the issue of new shares for the purpose of the limitations on the issue of new shares included in the allotment resolution and disapplication of pre-emption rights resolutions.
The effect of this resolution is to grant authority to the Company to purchase its own ordinary shares, up to a maximum of 35,684,750 ordinary shares. The authority shall expire (unless previously renewed, varied or revoked by the Company in general meeting) at the end of the next Annual General Meeting of the Company, or, if earlier, at the close of business on 31 January 2024. This represents approximately 10% of the number of ordinary shares in issue as at 5 October 2022 and the Company's exercise of this authority is subject to the stated upper and lower limits on the price payable, which reflect the requirements of the FCA's Listing Rules.
Under the Act, the Company can hold shares which have been purchased as treasury shares and either resell them for cash, cancel them, either immediately or at a point in the future, or use them for the purposes of its employee share schemes.
The Directors believe that it is desirable for the Company to have these choices available, as holding the purchased shares as treasury shares would give the Company the ability to re-sell or transfer them in the future and so provide the Company with additional flexibility in the management of its capital base. No dividends will be paid on and no voting rights will be exercised in respect of treasury shares.
It is not the Company's present intention to hold shares in treasury, in the event that any shares were to be purchased under this authority. Shares will only be purchased pursuant to this authority if the Directors consider such purchases to be in the best interests of shareholders generally and the purchases can be expected to result in an increase in earnings per share. The authority will only be used after careful consideration, taking into account market conditions prevailing at the time, other investment opportunities, appropriate gearing levels and the overall financial position of the Company.
This authority is in addition to the authority conferred on the Company by shareholders at the General Meeting held on 17 November 2021 and which is being used to implement the Company's Share Buyback Programme. It is the Company's current intention to continue to implement the existing Buyback Programme, and not to use this new authority. This authority is therefore sought to ensure the Directors maintain maximum flexibility in response to capital management. Please see page 15 of the FY2022 Annual Report for further information on the Company's Share Buyback Programme.
Shares held as treasury shares will not automatically be cancelled and will not be taken into account in future calculations of earnings per share (unless they are subsequently resold or transferred out of treasury). If any shares purchased by the Company are held in treasury and used for the purposes of its employee share schemes, the Company will count those shares towards the limits on the number of new ordinary shares which may be issued under such schemes.
As at 5 October 2022, there were 6,131,949 outstanding options and awards, granted under all share schemes operated by the Company, which, if vested, would represent 1.69% of the issued ordinary share capital of the Company. If the authorities to purchase the Company's own shares (both existing and sought) were exercised in full, that percentage would increase to 1.99%. For the purpose of these calculations, it has been assumed that all the outstanding options under the Sharesave Scheme and all the conditional share awards under the Long Term Incentive Plan and the Restricted Stock Plan will only be determined at their applicable vesting dates, subject to the satisfaction of the performance conditions and other requirements at those times.
With regard to the authorities sought under Resolutions 16 to 19, the Directors' intention would be to exercise the authorities given to them by the resolutions in accordance with the Share Capital Management Guidelines issued by the Investment Association in July 2016.
Under the Act, the Company may call a general meeting, other than an AGM, by giving 14 days' clear notice to shareholders. Under the Companies (Shareholders' Rights) Regulations 2009 this period is extended to 21 clear days unless the Company has obtained shareholder approval for a shorter period. This resolution would maintain the current position as agreed by shareholders at the 2021 AGM. The shorter notice period would not be used as a matter of routine but only where the flexibility was merited by the business of the meeting and was thought to be in the interests of shareholders as a whole. AGMs will still require at least 21 clear days' notice.
Part 14 of the Act requires companies to obtain shareholders' authority for donations to political parties or other political organisations or an independent election candidate in the UK totalling more than £5,000 in any twelve month period, and for any political expenditure in the UK, subject to limited exceptions. The definition of donation in this context is very wide and extends to bodies such as those concerned with policy review, law reform and the representation of the business community. It could include special interest groups, such as those involved with the environment, which the Company and its UK subsidiaries might wish to support, even though these activities are not designed to support or influence support for a particular political party.
It is the policy of the Company not to make political donations or incur political expenditure in the UK as those expressions are normally understood. However, to avoid inadvertent infringement of the Act, the Directors are seeking shareholders' authority for the Company and its UK subsidiaries (by virtue of the Act, the term 'subsidiary' in Resolution 21 is a reference to each UK subsidiary of the Company) to make political donations and to incur political expenditure in the UK up to a maximum aggregate amount of £50,000 for the period from the date of the Annual General Meeting to the end of the next Annual General Meeting of the Company, or, if earlier, at the close of business on 31 January 2024.
The statutory Report and Accounts for Smiths Group plc for its financial year of 2022 are called the FY2022 Annual Report. The Directors' Remuneration Report for 2022, which includes a summary of the Directors' Remuneration Policy, is contained in the FY2022 Annual Report. The first two items at the AGM relate to the approval of (1) the statutory Report and Accounts for 2022; and (2) the Director's Remuneration Report for 2022. Shareholders who have not elected to receive the FY2022 Annual Report in printed form may obtain copies by writing to the Secretary, Smiths Group plc, 4th Floor, 11-12 St James's Square, London SW1Y 4LB (e-mail: [email protected]) or by downloading them from the Company's website (www.smiths.com). Shareholders who wish to receive the printed FY2022 Annual Report (free of charge) in future years should write to the Company's Registrar, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, quoting Reference 0282.
All advance electronic proxy votes should be submitted by no later than 11.00am on 14 November 2022. If you return paper and electronic instructions, those received last by the Registrar before 11.00am on 14 November 2022 will take precedence. Electronic communication facilities are available to all shareholders and those that use them will not be disadvantaged. Any shareholders wishing to vote on the day of the AGM will need to attend the AGM in person or by proxy.
A proxy need not be a shareholder of the Company. A proxy form which may be used to make such appointment and give proxy instructions accompanies this notice. If you do not have a proxy form and believe that you should have one, or if you require additional forms, please contact Equiniti Limited on 0371 384 2943 if calling from the UK. From outside the UK, call the Equiniti overseas helpline on +44 121 415 7130. Shareholders wishing to appoint a proxy and register their proxy votes electronically ahead of the meeting should visit the website www.sharevote.co.uk. The on-screen instructions will give details on how to complete the appointment and voting process. To be effective, electronic proxy appointments and voting instructions must be received before 11.00am on 14 November 2022 (or, in the event of an adjournment, not later than 48 hours before the time of the adjourned meeting).
Important: in any case, to be effective, a proxy form or a proxy appointment submitted via the internet or a CREST Proxy Instruction must be received by the Company's Registrar before 11.00am on 14 November 2022 (or, in the event of an adjournment, not later than 48 hours before the time fixed for the holding of the adjourned meeting).
The statement of the rights of shareholders in relation to the appointment of proxies in paragraphs 2 and 3 above does not apply to Nominated Persons. The rights described in these paragraphs can only be exercised by shareholders of the Company. If you have been nominated to receive general shareholder communications directly from the Company, it is important to remember that your main contact in terms of your investment remains the registered shareholder or custodian or broker who administers the investment on your behalf. Therefore, any changes or queries relating to your personal details and holding (including any administration) must continue to be directed to your existing contact at your investment manager or custodian.
The Company cannot guarantee to deal with matters that are directed to them in error. The only exception to this is where the Company, in exercising one of its powers under the Act, writes to you directly for a response.
If you receive shareholder communications by post, you can do your bit for the environment by choosing to receive your voting instructions via email and voting electronically. To sign up for this service please scan the below QR Code.

RESOLUTIONS 4 TO 13 – ELECTION AND RE-ELECTION OF DIRECTORS
Appointed: 1 September 2022 Independent: Yes

Skills and experience: Richard's background in senior financial positions at large listed companies in a variety of sectors brings valuable insight to the Board's discussions. Richard holds a Bachelor of Science in Geography from Loughborough University and is a Fellow of the ICAEW.
Career experience: Richard is Chief Financial Officer of Bunzl plc, the specialist international distribution and services Group. Richard qualified as a Charted Accountant with Ernst & Young before moving to the investment bank Dresdner Kleinwort Benson. Prior to joining Bunzl in 2019, Richard held CFO positions at various multinational businesses including Inchcape plc, Coats Group plc and Bakkavor plc.
Appointed: 29 April 2022
Skills and experience: Clare has extensive experience working with and advising a broad range of industrial companies around the globe. She has particularly relevant experience in the sectors in which Smiths has strong positions, including Energy, Safety & Security and Aerospace. She holds a BA from Harvard University and an MBA from the Harvard Business School.
Career experience: Clare joined Smiths from Goldman Sachs where she spent more than 25 years, and was a Partner for more than a decade, and most recently Co-Head of the Global Industrials business. Prior to joining Smiths Clare had been a close adviser to the Group for a number of years, including having advised on the sale of Smiths Medical as well as having contributed to the development of the strategy announced at the November 2021 Capital Markets Event. Prior to Goldman Sachs, Clare was a consultant at McKinsey & Company.
Appointed: 1 August 2013 Independent: On appointment as Chairman

Skills and experience: Sir George has extensive experience of large, multi-industry businesses operating in global markets and has had a long career in engineering and innovation. As Chairman, Sir George ensures effective communication with key stakeholders and that the Board provides strong leadership and guidance for the Executive Management team. During the year, Sir George provided invaluable leadership on the sale of Smiths Medical alongside his support of the Finance Committee. He holds a PhD in Electrical Engineering.
Career experience: Sir George has held previous roles of Chairman and CEO at 3M Company, a US based global technology company and Dow Jones 30 component, Chairman and CEO of Brunswick Corporation and Chief Technology Officer for appliances, motors and controls at Emerson Electric Company. Sir George also brings nonexecutive experience to the Board, having served as Non-executive Director at PepsiCo Inc. and Hitachi Limited, and as Chairman of Stanley Black & Decker, Inc.

Skills and experience: Pam's experience in the areas of R&D, manufacturing, sales and marketing, commercial operations, supply-chain management and technology gained within large global businesses in strategically important regions for Smiths, further strengthen the Board's discussions on embedding world class operations. Pam holds a Bachelor of Science and a Master's degree in Chemical Engineering from Stevens Institute of Technology, New Jersey and an MBA in Marketing from Pace University, New York, USA.
Career experience: Pam is Executive Vice-President, Operations and Information Technology at AstraZeneca plc, a multinational pharmaceutical and biopharmaceutical company. Prior to joining AstraZeneca in 2015, Pam was President of MSD (Merck & Co., Inc.) in China. Pam has also previously held various engineering and project management positions at Universal Oil Products, Union Carbide Corporation and GAF Chemicals.
Non-executive Director Appointed: 19 September 2018 Independent: Yes

Skills and experience: Dame Ann's contribution to engineering research is internationally recognised, and her knowledge and background offer a different perspective to Board discussions, particularly as they relate to engineering, innovation and sustainability. Dame Ann has a degree in Mathematics and a PhD in Engineering.
Career experience: Dame Ann has had a distinguished academic career and is currently a Deputy Vice Chancellor and an Emeritus Professor of Mechanical Engineering at the University of Cambridge, where she served as Head of Engineering for five years until 2014. She served as the President and Chairman of Trustees of the Royal Academy of Engineering from 2014 to 2019 and as a Non-executive Director of BP plc from 2012 until May 2021, where she was a member of the Safety and Sustainability Committee.
Key
A Audit & Risk Committee R Remuneration & People Committee F Finance Committee Committee Chair
N Nomination & Governance Committee S Science, Sustainability & Excellence Committee
Smiths Group plc Notice of Annual General Meeting 2022 9
Non-executive Director Appointed: 2 April 2020 Independent: Yes

Skills and experience: Karin brings current executive experience of oil & gas, defence, security, and aerospace to the Board gained from a range of roles at large multinational groups. Karin has also provided valuable assistance and advice in executive and nonexecutive succession planning and ESG and sustainability matters. Karin holds a degree of Diploma Geophysics (MSc Geophysics) from the University of Hamburg, Germany.
Career experience: Karin is Group ESG, Culture and Business Transformation Director at BAE Systems plc. Prior to joining BAE she led one of the major international business divisions at Schlumberger, a multinational oil services company. Karin spent 20 years at Schlumberger, where she held a number of senior HR, marketing, technology and line management leadership positions across Europe, the Middle East and Asia.
Resolution 10 Paul Keel Chief Executive Appointed: 25 May 2021
Skills and experience: Paul has a strong track record of delivering results in other innovation-led and diversified global industrial technology businesses. His international experience positions him well to allow Smiths to deliver on its significant potential. He is a graduate of Carleton College and Harvard Business School.
Career experience: Prior to joining Smiths Paul worked at 3M Company between 2004 and 2020, within the US and UK. During this period, he led a number of global businesses including the \$5bn revenue Consumer Business Group and several industrial businesses ranging in size from \$400m in revenue to over \$1bn. He also led a number of enterprise functions including Manufacturing and Supply Chain, Marketing and Sales and Strategy and Business Development. In the short period between 3M and Smiths, Paul completed a variety of consulting projects. Paul's other experience includes roles of increasing responsibility at General Electric, McKinsey & Company and General Mills.
Appointed: 12 May 2014 Independent: Yes

Skills and experience: Bill has had a long and successful career in finance in the engineering sector, gaining an in-depth knowledge of global markets. Bill's extensive experience in global engineering businesses supports the Board's robust decision-making. Bill has a BA in economics and an MBA.
Career experience: Bill was appointed Chair of the Remuneration & People Committee on 1 July 2018, and as Senior Independent Director at the 2018 AGM. Bill has been Chair of the Finance Committee since it was formalised in November 2021. With effect from 1 February 2022 Bill was appointed to the Board of ICU Medical, Inc. in accordance with the terms of the shareholders agreement entered into with the sale of Smiths Medical. He is also a member of ICU's Audit and Compliance Committee. Bill was Group Finance Director at GKN plc, a global engineering group, until his retirement in 2014. At GKN he also held the roles of CEO of the Propulsion Systems Division, and CFO of the Aerospace Division. Prior to that, Bill spent 30 years at TRW, a US-based automotive and aerospace group, where he held various senior finance positions.
Other significant appointments: Senior Independent Director at Spectris plc and Lecturer at UCLA Anderson School of Management.

Skills and experience: Mark's extensive experience in corporate finance and capital markets supports Board discussion of the Group's portfolio management and strategy. He provided significant counsel during the sale of Smiths Medical through his support of the Transaction and now Finance Committee. Mark also brings non-executive experience to the Board, having served as senior independent director and audit committee chairman at several FTSE100 companies. Mark is a Chartered Accountant and has an MA in philosophy, politics and economics.
Career experience: Mark is a former senior investment banker and during his executive career he held various roles at Credit Suisse, including Chairman of UK Investment Banking. Mark served as a non-executive director on the Board of Kingfisher plc from 2012 to January 2021.
Appointed: 1 January 2017 Independent: Yes

Skills and experience: Noel has had a successful career in global business. He has extensive experience of the high-growth economies which are key markets for our growth strategy and has been invaluable in developing key strategic relationships in Asia since joining the Board. Noel has a BA in Economics.
Career experience: Noel was the Managing Director of Tata International Limited (TIL), a global trading and distribution company and a trading arm of the Tata Group, a privately owned multinational holding company. Under the terms of the Tata Group governance guidelines, he retired from the position of Managing Director on 12 November 2021. He was thereafter re-appointed as a Director and Non-Executive Chairman of TIL with effect from 15 November 2021.
Other significant appointments: Each of the following companies forms part of the Tata Group: Non-independent Non-executive Chairman at Tata Investment Corporation, Trent Ltd and Voltas Ltd. Non-independent Non-executive Vice Chairman at Tata Steel and Titan Company Ltd.
A Audit & Risk Committee R Remuneration & People Committee F Finance Committee Committee Chair
N Nomination & Governance Committee S Science, Sustainability & Excellence Committee
NOTES
NOTES
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.